NCT04603807进行中（未招募）3 期
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 217
- 试验地点
- 103
- 主要终点
- Progression-free survival (PFS) in participants with central nervous system (CNS) metastases at baseline
研究概览
简要总结
The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC). The participants will self-administer oral entrectinib or crizotinib as described in the protocol and local prescribing information. Treatments will continue until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically-confirmed diagnosis of advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC that harbors a documented ROS1 gene rearrangement.
- •No prior treatment with a ROS1 tyrosine kinase inhibitor, chemotherapy or other systemic therapy for advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC
- •Prior radiotherapy is allowed if more than 14 days have elapsed between the end of treatment and randomization
- •Measurable systemic disease according to RECIST v1.1
- •Participants with measurable and non-measurable CNS lesions per RECIST v1.1, including leptomeningeal carcinomatosis
- •Life expectancy of at least 12 weeks
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- •Adequate hematologic, renal, liver functions
- •Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
- •Ability to swallow entrectinib and crizotinib intact without chewing, crushing, or opening the capsules
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of <1% per year during the treatment period and for up to 5 weeks after the last dose of entrectinib or for at least 90 days after the last dose of crizotinib
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.
排除标准
- •Prior treatment with a ROS1 tyrosine kinase inhibitor, chemotherapy or other systemic therapy for advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC
- •NCI-CTCAE v5.0 Grade 3 or higher toxicities due to any prior therapy (excluding alopecia, fatigue, nausea and lack of appetite), which have not shown improvement and are strictly considered to interfere with current study drug
- •History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction ≤ 50% observed during screening for the study
- •History of prolonged corrected QTc interval
- •Peripheral sensory neuropathy ≥ Grade 2
- •Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis
- •Previous malignancy within the past 3 years
- •Incomplete recovery from any surgery prior to the start of study treatment
- •Active GI disease (e.g., Crohn's disease, ulcerative colitis or short gut syndrome) or other malabsorption syndrome that would reasonably impact drug absorption
- •History of prior therapy-induced pneumonitis
- •Any condition (in the past 3 months) e.g., myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, stroke, symptomatic bradycardia, or uncontrolled arrhythmias requiring medication
- •Known active infections (bacterial, fungal or viral, including human immunodeficiency virus positive)
- •History of hypersensitivity to any of the additives in the entrectinib and/or crizotinib drug formulations
- •Pregnant or lactating women
- •Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness
- •Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications.
研究组 & 干预措施
Crizotinib
Active Comparator
Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
干预措施: Crizotinib (Drug)
Entrectinib
Experimental
Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
干预措施: Entrectinib (Drug)
结局指标
主要结局
Progression-free survival (PFS) in participants with central nervous system (CNS) metastases at baseline
时间窗: Up to 7 years
PFS is defined as the time from randomization to the first documented disease progression (extracranial or intracranial) or death from any cause whichever occurs first determined by a blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
次要结局
- Overall response rate (ORR)(Up to 7 Years)
- Duration of response (DOR)(Up to 7 Years)
- Percentage of participants with impact on lung cancer-specific symptoms assessed by the EORTC QLQ-LC13(Up to 7 Years)
- Overall survival (OS)(Up to 7 Years)
- Duration of response in the CNS (CNS-DOR) in participants with CNS metastases at baseline(Up to 7 Years)
- Percentage of participants with Adverse Events and Serious Adverse Events and Adverse Events leading to dose modifications/interruptions, study drug withdrawal or death(Up to 7 Years)
- Progression-free survival (PFS)(Up to 7 years)
- Progression-free survival in the Central Nervous System (CNS-PFS)(Up to 7 Years)
- Percentage of participants with confirmed deterioration as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)(Up to 7 Years)
- Objective response rate in the CNS-ORR in participants with CNS metastases at baseline(Up to 7 Years)
研究者
研究点 (103)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Carcinoma, Non-Small-Cell LungNCT06140836Bristol-Myers Squibb190
Unknown
3 期
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationNon-Small Cell Lung CancerNCT02001896Xinjiang Medical University60
已完成
1 期
A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy ParticipantsHealthy VolunteersNCT03796260Genentech, Inc.14
Unknown
2 期
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT03387904The First Affiliated Hospital of Zhengzhou University120
终止
3 期
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerNon Squamous, Non-small-cell Lung CancerNCT01244191Daiichi Sankyo1,048